http://repository.mtu.edu.et/xmlui/handle/123456789/65 2026-05-27T18:40:43Z 2026-05-27T18:40:43Z Asnake Kebede, Molla Tadesse Mengistu, Yewondwosen Yacob Loge, Biruk Alemu Eshetu, Misikr Pawlos Shash, Erkihun Tolera Wirtu, Amenu http://repository.mtu.edu.et/xmlui/handle/123456789/227 2025-01-28T11:11:46Z 2024-09-02T00:00:00Z

Determinants of Disease Progression in Autosomal Dominant Polycystic Kidney Disease Asnake Kebede, Molla; Tadesse Mengistu, Yewondwosen; Yacob Loge, Biruk; Alemu Eshetu, Misikr; Pawlos Shash, Erkihun; Tolera Wirtu, Amenu Background: Despite its severity, there has been a lack of adequate study on autosomal dominant polycystic kidney disease (ADPKD) in Ethiopia. This study assessed the clinical profile and determinant factors contributing to renal disease progression. Methods: A retrospective study was conducted on 114 patients for 6 years in Addis Ababa. Patients with ADPKD who had follow-up visits at two health centers were included. Results: The mean age at diagnosis was 42.7 ± 12.7 years, with 43% reporting a positive family history of ADPKD. Approximately 22 patients (20%) developed endstage renal disease, and 12 patients died. The mean estimated glomerular filtration rate at the initial visit was 72.4 mL/min/1.73 m2 . The key risk factors associated with disease progression included younger age at diagnosis [adjusted Odds Ratio (aOR): 0.92, 95% CI: 0.87–0.98; p = 0.007], male gender (aOR: 4.5, 95% CI: 1.3–15.95, p = 0.017), higher baseline systolic blood pressure (aOR: 1.05, 95% CI: 1.01–1.10, p = 0.026), and the presence of comorbidities (aOR: 3.95, 95% CI: 1.10–14.33, p = 0.037). The progression of renal disease in ADPKD patients significantly correlates with age at diagnosis, gender, presence of comorbidities, and higher baseline systolic blood pressure. Conclusions: These findings underscore the importance of early detection and management of hypertension and comorbidities in ADPKD patients to mitigate disease progression and improve treatment outcomes.

2024-09-02T00:00:00Z Habtemariam, Yosef Asnake, Molla Alemu, Misikr Pawlos Shash, Erkyehun Worku Tessema, Tsegaw Girma Tesso, Zerubabel Hawlet, Michael http://repository.mtu.edu.et/xmlui/handle/123456789/225 2025-01-27T13:52:24Z 2024-03-14T00:00:00Z

Plasmodium Vivax as a Causative Agent for Cerebral Malaria in a Group of Adults at Mizan Tepi Teaching Hospital: Case Series Habtemariam, Yosef; Asnake, Molla; Alemu, Misikr; Pawlos Shash, Erkyehun; Worku Tessema, Tsegaw; Girma Tesso, Zerubabel; Hawlet, Michael In 2022, there were 249 million cases of malaria globally, resulting in 608,000 deaths. The majority of cases and deaths occurred in the WHO (World Health Organization) African Region. A study in our region found that, out of 263,476 individuals, 148,734 had P. falciparum, 106,946 had P. vivax, and 7,796 had mixed infections. The prevalence of P. falciparum (Plasmodium falciparum) was 8.97% and P. vivax (Plasmodium Vivax) was 7.94%. Although there have been a few reported cases of cerebral malaria caused by P. vivax, there is currently no comprehensive analysis of such cases. All the cases that have been reported so far involved individuals living in malaria-endemic areas, who presented with symptoms characteristic of cerebral malaria. Cerebral malaria was diagnosed based on the clinical algorithm which WHO used except we used P. vivax instead of P. falciparum The diagnosis of these cases was confirmed through thin blood film examination and Rapid Diagnostic Tests (RDTs). Therefore, this report aims to provide additional data on the occurrence of P. vivax as a cause of cerebral malaria. It also recommends further studies to reassess the current clinical case definition of cerebral malaria mainly in endemic areas as it affects patient treatment outcome. Keywords: cerebral malaria, P. Vivax and Blood Film

2024-03-14T00:00:00Z Asnake, Molla Henock, Andualem Abayneh, Menigistu Getu, Shimelis Hailemariam5, Shewangizaw Endalkachew, Biruk Zerihun, Dessalegn http://repository.mtu.edu.et/xmlui/handle/123456789/224 2025-01-27T11:35:27Z 2022-12-20T00:00:00Z

Acute interstitial nephritis with Prothionamide Asnake, Molla; Henock, Andualem; Abayneh, Menigistu; Getu, Shimelis; Hailemariam5, Shewangizaw; Endalkachew, Biruk; Zerihun, Dessalegn Among drug-related complications, drug-related nephrotoxicity is the commonest. It is the cause for 7% of all drug-related toxicities among inpatients and accounts for 20% to 30% of acute renal failure. Acute interstitial nephritis is one of the drug-related adverse reactions and occurs due to a drug-related type 4 hypersensitivity reaction. In this case report, we reported acute interstitial nephritis that causes acute renal failure (acute kidney injury) in a patient taking Prothionamide therapy. This drug-related side effect had not been reported. In this case report, we report a patient who develops fatigability, rash, and intermittent fever after 14 days of taking the drug Prothionamide. The main aims of this case report are to use it as a pharmacovigilance report for drug-producing companies and to consider a further study on this side effect. It is also an alert for clinicians to consider this side effect when patients develop acute interstitial nephritis while taking Prothionamide.

2022-12-20T00:00:00Z Tesso; Gossaye; Bekena; Kebede; Besir;Dabe, Zerubabel Ts; Tariku Yg; Dereje sb; Molla Ak; Fikretsion Db; Nikodimos Ed http://repository.mtu.edu.et/xmlui/handle/123456789/217 2025-01-23T13:55:12Z 2024-11-11T00:00:00Z

Plasmodium falciparum neonatal malaria with atypical presentation: a case series from southwestern Ethiopia Tesso; Gossaye; Bekena; Kebede; Besir;Dabe, Zerubabel Ts; Tariku Yg; Dereje sb; Molla Ak; Fikretsion Db; Nikodimos Ed Background Neonatal malaria is defined as the detection of asexual stages of Plasmodium species in the cord blood within the first 28 days of life. It can be congenital or acquired through mosquito bites or blood transfusions. Neonates are generally considered to be relatively protected due to the multiple innate and acquired physiological protective effects present in neonates. However, in areas where malaria is endemic, the prevalence of malaria in neo- nates is high. The predominant clinical feature of malaria in neonates is fever. Other clinical manifestations of neonatal malaria include respiratory distress, pallor and anaemia, hepatomegaly, refusal to feed, jaundice and diarrhoea. Atypi- cal presentations without fever can lead to inaccurate diagnosis and contribute to neonatal morbidity and mortality. Neonates from endemic areas with any of the above symptoms should be screened for malaria. Case presentation We present a series of three cases of neonatal Plasmodium falciparum malaria that presented atypically without febrile episodes and were diagnosed and managed at Mizan-Tepi University Teaching Hospital between July and September 2023. The first patient presented with vomiting, refusal to feed, pallor, severe anaemia, and splenomegaly. The second patient presented with an inconsolable cry, failure to pass feces, abdominal distention, and anaemia. The third patient presented with vomiting and anaemia. All patients received a 7-day course of intrave- nous artesunate; the first patient also received a blood transfusion. All patients recovered and were discharged. Conclusions Partial immunity resulting from repeated malaria infections in endemic regions may result in the trans- fer of high levels of maternal Immunoglobulin G (IgG) antibodies through the placenta and can produce different atypical clinical presentations. In malaria-endemic areas, neonates presenting with any of the presenting signs and symptoms of malaria, including afebrile presentation, require malaria screening to avoid delays in diagnosis

2024-11-11T00:00:00Z